journal cover

Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Blood

Nov 13, 2019

Benjamin L LampsonMatthew S Davids

Get paper from

Abstract

Montegaard: Pharmacyclics: Consultancy; Janssen: Consultancy. Jacobson:Kite, a Gilead Company: Consultancy, Honoraria, Other: Travel Expenses, Research Funding; Novartis: Consultancy, Honoraria, Other: Travel Expenses; Pfizer: Consultancy, Research Funding; Humanigen: Consultancy, Other...read more

Mentioned in this Paper

Biotechnology
Burning Mouth Syndrome
Drug Industry
Combination Drug Therapy
Pharmaceutical Preparations
Chronic Lymphocytic Leukemia
Research
Triglycerides
Tau Proteins
No Doz
1
Paper Details
References
  • References
  • Citations
  • finger pointing at paper

    References currently unavailable

    We're still populating references for this paper, please check back later.
  • References
  • Citations
  • quote and clock

    No citations available

    This paper may not have been cited yet.

Similar Papers Found In These Feeds

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a chronic neurodegenerative disease. This feed focuses on the underlying role of Tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's.

Bioinformatics in Biomedicine

Bioinformatics in biomedicine incorporates computer science, biology, chemistry, medicine, mathematics and statistics. Discover the latest research on bioinformatics in biomedicine here.

Tauopathies

Tauopathies are neurodegenerative disorders caused due to misfolding and aggregation of the tau protein in neurofibrillary tangles in the brain. Discover the latest research on tauopathies here.

Tau Aggregation: Genomics

Tau Aggregation is an important characteristic in some neurodegenerative disorders, including Alzheimer’s Disease. Discover the latest research using genomics to understand Tau Aggregation.

Leukemia, B-Cell

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute focuses on advancing cancer tratment through supporting clinical trials and translational research. Follow this feed to stay up to date on research from this institute.

© 2019 Meta ULC. All rights reserved

Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Blood

Nov 13, 2019

Benjamin L LampsonMatthew S Davids

PMID: 31723987

DOI: 10.1182/blood-2019-127506

Abstract

Montegaard: Pharmacyclics: Consultancy; Janssen: Consultancy. Jacobson:Kite, a Gilead Company: Consultancy, Honoraria, Other: Travel Expenses, Research Funding; Novartis: Consultancy, Honoraria, Other: Travel Expenses; Pfizer: Consultancy, Research Funding; Humanigen: Consultancy, Other...read more

Mentioned in this Paper

Biotechnology
Burning Mouth Syndrome
Drug Industry
Combination Drug Therapy
Pharmaceutical Preparations
1

Related Papers

Paper Details
References
  • References
  • Citations
  • finger pointing at paper

    References currently unavailable

    We're still populating references for this paper, please check back later.
  • References
  • Citations
  • quote and clock

    No citations available

    This paper may not have been cited yet.

Get paper from

/papers/preliminary-safety-and-efficacy-results-from-a/31723987